On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
- COMMENTARY／Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
- COMMENTARY／Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
- COMMENTARY／Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
- COMMENTARY／Reform of Ethical Drug Distribution Practices
September 1, 2008
- COMMENTARY／Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
- COMMENTARY／Development Race for RNAi Therapeutics Heating Up in Japan
August 4, 2008
- COMMENTARY 4 articles
July 28, 2008
- COMMENTARY／Industry Needs More Creative Thinking: NHI Pricing System Reform
July 21, 2008
- COMMENTARY／Will Fiscal Rehabilitation Policy Be Maintained?
July 7, 2008
- COMMENTARY／Daiichi Sankyo Surprises the World by Announcing Acquisition of Ranbaxy
June 30, 2008
- Pharmaceutical Partnerships in Japan for Regulatory and Commercial Success
June 30, 2008
- COMMENTARY 4 articles
June 9, 2008
- COMMENTARY／Shaking Pharmaceutical Administration System
May 19, 2008
- COMMENTARY／Personnel Strategy -New Graduates or Work-Ready MRs?
April 21, 2008
- COMMENTARY／Industry-Academia Cooperation Essential for Practical Use of iPS Cells
April 21, 2008
- COMMENTARY／Improvement of Drug Distribution Business Practices Goes into Crucial Stretch
April 14, 2008
- COMMENTARY／Mr Kodama Owes His Sweeping Victory to Members' Desire for Change: JPA
March 31, 2008
- COMMENTARY／Most Mainstay Products Avoid Deep Price Cuts in FY2008 NHI Price Revision
March 31, 2008
- Methodologic Issues in the Clinical Trial Study of Depression
March 24, 2008
ページ
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…